Investigational Drug Information for substance P
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug substance P?
substance P is an investigational drug.
There have been 9 clinical trials for substance P.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Hypertension, Vascular Diseases, and Heart Diseases. The leading clinical trial sponsors are University of Edinburgh, NHS Lothian, and Vanderbilt University.
There are two hundred and twelve US patents protecting this investigational drug and four international patents.
Summary for substance P
| US Patents | 212 |
| International Patents | 4,877 |
| US Patent Applications | 1,320 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 4,709 |
| Clinical Trial Progress | Phase 1 (2018-11-15) |
| Vendors | 31 |
Recent Clinical Trials for substance P
| Title | Sponsor | Phase |
|---|---|---|
| Substance P Challenge in Healthy Participants | GlaxoSmithKline | N/A |
| Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 | Vanderbilt University Medical Center | Phase 4 |
| Neuropeptide Therapy of Recent Onset Type 1 Diabetes | Vanilloid Genetics Inc. | Phase 1 |
Clinical Trial Summary for substance P
Top disease conditions for substance P
Top clinical trial sponsors for substance P
US Patents for substance P
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| substance P | See Plans and Pricing | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| substance P | See Plans and Pricing | Use of GPR83 to identify pruritus-related substances | University of Miyazaki (Miyazaki, JP) | See Plans and Pricing |
| substance P | See Plans and Pricing | Compositions and methods for treating chronic inflammation and inflammatory diseases | Infirst Healthcare Limited (London, GB) | See Plans and Pricing |
| substance P | See Plans and Pricing | Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists | Scherer; Warren (Lutz, FL) | See Plans and Pricing |
| substance P | See Plans and Pricing | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| substance P | See Plans and Pricing | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Reset Therapeutics, Inc. (South San Francisco, CA) | See Plans and Pricing |
| substance P | See Plans and Pricing | Crystalline forms of fosnetupitant | Helsinn Healthcare SA (Lugano/Pazzallo, CH) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for substance P
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| substance P | Australia | AU2007226627 | 2026-03-10 | See Plans and Pricing |
| substance P | Australia | AU2007260787 | 2026-03-10 | See Plans and Pricing |
| substance P | Canada | CA2646478 | 2026-03-10 | See Plans and Pricing |
| substance P | Canada | CA2655372 | 2026-03-10 | See Plans and Pricing |
| substance P | Canada | CA2683145 | 2026-03-10 | See Plans and Pricing |
| substance P | European Patent Office | EP1996622 | 2026-03-10 | See Plans and Pricing |
| substance P | European Patent Office | EP2044118 | 2026-03-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
